Personal Genome Diagnostics, Inc.

Baltimore, MD 21205

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $952K
First Award Date 08/01/15
Most Recent Award Date 09/22/17

Key Personnel

Last Name Name Awards Contact
SAUSEN MARK SAUSEN 3
ZHANG THERESA ZHANG 3

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/22/17 - 03/21/18

Abstract Immune checkpoint inhibitors have recently emerged as a revolution in cancer care, providing the potential for durable response and improved survival for numerous cancer patients across multiple cancer types. However, only 10-20% of patients who are treated with checkpoint inhibitors have responded in most cancer types, necessitating bi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/19/16 - 03/18/17

Checkpoint inhibitors yield a significant clinical benefit for a subset of cancer patients. Given the high cost of these therapies and the time required to determine whether a therapy is efficacious, tests that can identify patients who are most likely to benefit are urgently needed. Supported by a strong biological rationale, tumor mutational l...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/23/15 - 02/29/16

DESCRIPTION (provided by applicant) Development of a Non-Invasive Plasma-Based Test to Stratify Non-Small Cell Lung Cancer Patients for Targeted Therapies Lung cancer is the most common and lethal cancer worldwide, accounting for 1.8 million new cases and 1.6 million deaths in 2012 (www.lung.org). In the United States alone, there will be approx...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/01/15 - 03/31/16

DESCRIPTION (provided by applicant): With over 1.2 million new cases and over 608,000 deaths annually, colorectal cancer (CRC) is the third most common cancer and the third highest cause of cancer death in the developed world. CRC patients are classified into stage I through IV depending on the extent of their disease. Approximately 25% of CRC p...